Richard D. Gill

Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA.

Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

TruTouch Technologies, Inc. develops, manufactures, and sells versatile noninvasive alcohol testing systems for both existing and emerging markets. It provides TruTouch system, an alcohol deterrence detection system, which is used in workforce workplace safety, medical diagnostic, alcohol point-of-sale liability reduction, law enforcement, and industrial safety sectors. The company was founded by Trent Daniel Ridder and Benjamin J. Ver Steeg on September 6, 2005 and is headquartered in Albuquerque, NM.

SynDevRx, Inc. develops treatments for metabolic-related diseases. Its product includes SDX-7320, a polymer conjugate of fumagillol that releases a pharmacologically active small molecule fumagillol derivative in vivo. The company was founded by James M. Shanahan and Bradley J. Carver and is headquartered in Cambridge, MA.

BTG International Inc. (BTG International) is a venture capital subsidiary of BTG Ltd founded in 1981. The firm is headquartered in West Conshohocken, Pennsylvania.

BioLegend CNS, Inc. provides monoclonal antibodies used in the research of cancer, infectious disease and neurodegenerative diseases. The company is headquartered in Boston, MA.

NABsys, Inc. developed DNA analysis sequencing platform. Its platform used solid-state nanodetectors to analyze single DNA molecules, revealing both location and identity of DNA sequences over long distances. The firm system was designed to set new standards for accuracy, speed and scalability, offering compelling advantages for the analysis of genome structural variation, genome mapping, and both targeted and whole genome sequencing. The company was founded by Xinsheng Sean Ling, Leon N. Cooper and Barrett Bready in 2004 and was headquartered in Providence, RI.